9th International Conference on HLA-G July 4th – 5th 2022 Fondation Singer-Polignac, 43 Avenue Georges Mandel, 75116 Paris Invectys will be…
Invectys, MD Anderson and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development Houston, Texas, USA – June 16, 2022 – Invectys, Inc. (Invectys),…
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS Houston, Texas, USA – April 11, 2022 (GLOBE NEWSWIRE) –…
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board Houston, TX, USA, March 8, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston, Texas,…
Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development Houston, TX, USA, March 1st, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston,…
Modified autologous CAR T cells to eliminate HLA-G-bearing cancer cells a) What are CAR-T cells? Chimeric Antigen Receptors (CARs) are artificial receptors, derived…
Invectys to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference Houston, Texas, USA – January 6th, 2022 (GLOBE NEWSWIRE) –…
Houston, Texas, USA, Dec. 16, 2021 (GLOBE NEWSWIRE) — Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development…
